

PATENT
678503-2006.2
USSN 09/612,852

AMENDMENT TO THE CLAIMS

Prior to continued examination, please enter the following amendments to the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

Cancel claims 1, 5, 6 and 8-14 without prejudice.

1-15 (Canceled)

16. (Previously Presented) An adenovirus (Ad) with novel vector tropism and ablation of native Ad receptor tropism due to the expression of a fiber replacement protein, said fiber replacement protein comprises:

- a) an amino-terminal portion comprising an adenoviral fiber tail domain that associates with the penton base of the adenovirus;
- b) a fiber-fibritin chimeric rod trimeric protein that provides trimerization function; and
- c) a carboxy-terminal portion comprising a targeting ligand.

17. (Previously Presented) The adenovirus of claim 16 wherein the fiber-fibritin chimeric rod trimeric protein is a fiber-fibritin-6His chimera.

18. (Previously Presented) The adenovirus of claim 16 wherein the fiber-fibritin chimeric rod trimeric protein is a fiber-fibritin-RGD-6His chimera.

19. (Previously Presented) The adenovirus of claim 16, wherein said fiber replacement protein retains trimerism when a sequence encoding a targeting ligand is incorporated into the carboxy-terminus.

20. (Previously Presented) The adenovirus of claim 16, wherein said fiber replacement protein is soluble.

21. (Previously Presented) The adenovirus of claim 16, wherein said fiber replacement protein contains isoleucine trimerization motif.

22. (Previously Presented) The adenovirus of claim 16, wherein said rod-like trimeric protein contains neck region peptide from human lung surfactant D.

23. (Previously Presented) The adenovirus of claim 16, wherein said fiber replacement protein is an artificial protein having a coiled coil secondary structure, wherein said secondary structure is stable because of multiple interchain interactions.

PATENT
678503-2006.2
USSN 09/612,852

24. (Previously Presented) The adenovirus of claim 16, wherein said targeting ligand is selected from the group consisting of physiological ligands, anti-receptor antibodies, cell-specific peptides and single chain antibodies.

25. (Previously Presented) The adenovirus of claim 16, wherein said adenovirus comprises a transgene.

26. (Previously Presented) The adenovirus of claim 25, wherein the transgene is a herpes simplex virus thymidine kinase gene